- Home
- NSTS vs KRRO Comparison
NSTS vs KRRO Comparison
Compare NSTS & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | KRRO |
|---|---|---|
| Founded | 1921 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.7M | 58.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NSTS | KRRO |
|---|---|---|
| Price | $11.86 | $7.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $74.17 |
| AVG Volume (30 Days) | 6.4K | ★ 443.1K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,762,000.00 | $7,371,000.00 |
| Revenue This Year | N/A | $144.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 57.78 | N/A |
| 52 Week Low | $10.72 | $5.20 |
| 52 Week High | $13.32 | $55.89 |
Technical Indicators
Market Signals| Indicator | NSTS | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 68.20 | 32.61 |
| Support Level | $11.70 | $7.63 |
| Resistance Level | $11.89 | $8.57 |
| Average True Range (ATR) | 0.14 | 0.68 |
| MACD | 0.04 | 1.30 |
| Stochastic Oscillator | 84.94 | 73.52 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.